Hemostasis Products Global Market Report 2024

The hemostasis products market size has grown strongly in recent years. It will grow from $1.59 billion in 2023 to $1.7 billion in 2024 at a compound annual growth rate (CAGR) of 7.0%. The growth observed in the historical period can be attributed to an increase in surgical procedures, a growing aging population, a rise in the incidence of hemophilia, the expansion of healthcare infrastructure, and an increased awareness of blood clotting disorders.

The hemostasis products market size is expected to see strong growth in the next few years. It will grow to $2.16 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The anticipated growth in the forecast period can be attributed to the increasing demand for minimally invasive surgeries, a global rise in trauma cases, the expansion of hemostasis applications in chronic diseases, a shift towards ambulatory surgical centers, and the focus on personalized medicine and biomarker research. Key trends expected in the forecast period include technological innovations in hemostasis, advancements in hemostatic technologies, a growing preference for minimally invasive procedures, an increasing incidence of chronic diseases, and a heightened focus on biodegradable hemostatic agents.

The expected increase in the prevalence of blood disorders is poised to drive the growth of the hemostasis products market in the foreseeable future. Blood disorders, or hematologic disorders, encompass various medical conditions affecting the composition, function, and behavior of blood and its components. Hemostasis products play a crucial role in managing clotting and bleeding processes associated with different blood disorders, addressing both excessive bleeding (hemorrhage) and excessive clotting (thrombosis). According to the Leukemia Foundation's June 2021 report, approximately 110,000 people in Australia were living with blood disorders in 2021, a number expected to surpass 275,000 cases by 2035 due to the rising incidence of blood cancer and disorders in the country. Thus, the growing prevalence of blood disorders is a key driver fueling the growth of the hemostasis products market.

The anticipated rise in the prevalence of cardiac disorders is expected to contribute significantly to the growth of the hemostasis products market. Cardiac disorders encompass a broad category of medical conditions affecting the heart and blood vessels. Hemostasis products play a vital role in managing bleeding associated with cardiac disorders and in preventing and treating such conditions. By minimizing blood loss, these products reduce the need for blood transfusions and potential complications related to cardiac disorders. According to the Centers for Disease Control and Prevention (CDC) in May 2023, a heart attack occurs every 40 seconds in the United States, with 805,000 Americans experiencing a heart attack each year, 605,000 of whom are facing their first episode. Therefore, the increasing prevalence of cardiac disorders is a significant driver propelling the growth of the hemostasis products market.

The hemostasis products market is expected to encounter a notable challenge in the form of off-label product usage. This practice involves utilizing hemostatic products for purposes beyond their approved indications, potentially introducing risks and uncertainties in hemostatic treatment. Off-label marketing, as highlighted by the National Library of Medicine, undermines innovation by allowing manufacturers to expand product usage without the necessary research or safety testing. This practice may pose challenges to companies that diligently conduct research and development efforts. Consequently, off-label product usage poses a hindrance to the growth of the hemostasis products market.

Major companies in the hemostasis products market are focusing on the development of innovative drugs, including the Nexpowder endoscopic hemostasis system, and obtaining approvals for a comprehensive range of active and passive hemostatic products for bleeding control. The endoscopic hemostasis system is a medical device and technique used to control bleeding in the gastrointestinal (GI) tract during endoscopic procedures. Medtronic plc, a US-based medical device company, received clearance from the U.S. Food and Drug Administration in September 2022 for the Nexpowder Endoscopic Hemostasis System, designed for the treatment of nonvariceal upper GI bleeding. This innovative hemostatic product has the potential to make a significant impact on the treatment of nonvariceal upper GI bleeding due to its ease of use, effectiveness, and good tolerability.

In July 2021, Baxter International Inc., a US-based healthcare company, acquired assets such as the Polysaccharide Hemostatic System from CryoLife Inc. for $60.8 million. This strategic acquisition aims to expand Baxter's hemostasis product portfolio, gain access to PerClot's technology, and enhance its position in the hemostasis market. CryoLife Inc., a US-based medical device company, specializes in developing and manufacturing products for hemostasis.

Major companies operating in the hemostasis products market report are Pfizer Inc., Abbott Laboratories, Thermo Fisher Scientific Inc., Medtronic plc, Johnson And Johnson Pvt. Ltd., Siemens Healthineers, Becton Dickinson and Company (BD), Stryker Corporation, Baxter International Inc., Boston Scientific Corporation, F. Hoffmann-La Roche Ltd., BBraun Melsungen AG, Fresenius Kabi AG, Zimmer Biomet Holdings Inc., Olympus Corporation, Grifols S.A., Terumo BCT Inc., Smith And Nephew plc, Ethicon Suture Laboratories, Hologic Inc., Cook Medical, Teleflex Incorporated, Integra LifeSciences Corporation, Haemonetics Corporation, Z-Medica LLC, Tricol Biomedical, Hem Con Medical Technologies Inc., Hemostasis LLC, C. R. Bard Inc., CuraMedical BV.

North America was the largest region in the hemostasis products market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hemostasis products market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the hemostasis products market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hemostasis products market consists of sales of hemostatic agents, hemostatic powders, hemostatic sponges, collagen, oxidized regenerated cellulose, gelatin, polysaccharide, flowable complex, thrombin complex, fibrin complex, synthetic sealants, and fresh frozen plasma. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The primary categories of hemostasis products include topical hemostasis products, infusible hemostasis products, and advanced hemostasis products. Topical hemostasis products encompass medical substances or materials specifically designed to halt or regulate bleeding. They find applications in various scenarios such as trauma, surgery, hemophilia, myocardial infarction, and others, with major end-users including hospitals, clinics, and others.

The hemostasis products market research report is one of a series of new reports that provides hemostasis products market statistics, including hemostasis products industry global market size, regional shares, competitors with a hemostasis products market share, detailed hemostasis products market segments, market trends and opportunities, and any further data you may need to thrive in the hemostasis products industry. This hemostasis products market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.